Ardsley Advisory Partners LP Biomarin Pharmaceutical Inc Transaction History

Ardsley Advisory Partners LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$71.87 - $131.03 $215,610 - $393,090	-3,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $238,650 - $372,660	3,000 New	3,000 $370,000
Q2 2018 Aug 14, 2018	SELL	$76.01 - $99.03 $760,100 - $990,300	-10,000 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $242,280 - $285,390	3,000 Added 42.86%	10,000 $892,000
Q2 2017 Sep 21, 2017	BUY	N/A	7,000	7,000 $636,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Ardsley Advisory Partners LP, based on Form 13F filings with the SEC.

Stay updated on Ardsley Advisory Partners LP with notifications on news.